Replies to post #322573 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

It is possible for Anavex to make a similar presentation at the AAIC from an interim analysis of their OLE extension trial with at least 100 patients over a longer time frame of treatment,

On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC, including a brief Q&A session. This oral presentation will announce results of an interim analysis on safety and cognition for the first 50 patients with Alzheimer’s disease to complete 9 months of open-label treatment.

Good luck and GOD bless,